Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
CorrectionErratum

Correction to “Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro CYP Induction Studies Including Impact on Drug Interaction Risk Assessment”

Drug Metabolism and Disposition April 2021, 49 (4) 344; DOI: https://doi.org/10.1124/dmd.120.000055err
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    TABLE 3

    Summary of AFE comparing Emax, EC50, or Emax/EC50 at earlier time points (6, 12, 24, or 48) to 72 h

    AFE’s were summarized for each cytochrome P450 isoform and respective inducers: CYP1A2 (omeprazole, phenobarbital), CYP2B6 (efavirenz, phenobarbital, rifampicin), CYP2C9 (rifampicin), CYP3A4 (efavirenz, rifampicin). ND: Not determined.

    AFE of Parameter Estimate (Emax, EC50, or Emax/EC50) Determined at 6, 12, 24, or 48 h Compared with Estimate at 72 h
    Parameter EstimateCytochrome P450 Isoform6 h12 h24 h48 h
    mRNAActivitymRNAActivitymRNAActivitymRNAActivity
    Emax AFE (n)CYP1A20.33 (7)0.10 (6)0.42 (8)0.35 (7)0.77 (10)0.48 (8)0.89 (10)0.81 (13)
    CYP2B60.42 (20)0.10 (7)0.59 (15)0.21 (9)0.64 (18)0.45 (10)0.96 (18)0.90 (13)
    CYP2C90.49 (2)—0.84 (3)—0.94 (4)—1.0 (4)—
    CYP3A40.29 (9)0.22 (4)0.76 (9)0.30 (9)0.90 (12)0.55 (10)0.97 (12)0.90 (10)
    Overall AFE (n)0.36 (38)0.13 (17)0.60 (35)0.27 (25)0.76 (44)0.50 (28)0.95 (44)0.87 (36)
    % Within twofold (n)39 (15)0 (0)51 (18)28 (7)68 (30)36 (10)86 (38)89 (32)
    EC50 AFE (n)CYP1A20.93 (5)0.32 (6)0.64 (8)1.1 (7)1.24 (10)0.56 (7)0.75 (10)0.94 (12)
    CYP2B61.82 (19)1.2 (8)1.99 (12)1.3 (9)1.30 (18)1.0 (11)1.07 (18)1.0 (12)
    CYP2C92.0 (1)—1.1 (3)ND2.4 (3)—0.70 (4)ND
    CYP3A41.8 (8)1.1 (3)2.0 (9)4.1 (9)1.6 (12)2.7 (10)1.1 (10)1.5 (10)
    Overall AFE (n)1.64 (33)0.72 (17)1.43 (32)1.89 (25)1.43 (43)1.24 (28)0.96 (42)1.11 (34)
    % Within twofold (n)42 (14)35 (6)44 (14)32 (8)49 (21)21 (6)70 (30)44 (15)
    Emax/EC50 AFE (n)CYP1A20.32 (5)0.34 (4)0.32 (8)0.54 (5)0.35 (10)0.68 (7)0.45 (8)0.84 (11)
    CYP2B60.21 (18)0.083 (8)0.20 (11)0.16 (9)0.52 (17)0.42 10)0.95 (16)0.94 (13)
    CYP2C90.19 (1)—0.77 (3)—0.43 (3)—1.4 (4)—
    CYP3A40.22 (7)0.071 (2)0.37 (9)0.076 (8)0.55 (12)0.20 (10)0.94 (10)0.60 (10)
    Overall AFE (n)0.23 (31)0.12 (14)0.43 (31)0.16 (22)0.55 (42)0.36 (27)0.99 (38)0.79 (34)
    % Within twofold (n)19 (6)14 (2)48 (15)18 (4)55 (23)41 (11)87 (33)59 (20)
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 49 (4)
Drug Metabolism and Disposition
Vol. 49, Issue 4
1 Apr 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Correction to “Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro CYP Induction Studie…
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
CorrectionErratum

Correction to “Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro CYP Induction Studies Including Impact on Drug Interaction Risk Assessment”

Drug Metabolism and Disposition April 1, 2021, 49 (4) 344; DOI: https://doi.org/10.1124/dmd.120.000055err

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
CorrectionErratum

Correction to “Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro CYP Induction Studies Including Impact on Drug Interaction Risk Assessment”

Drug Metabolism and Disposition April 1, 2021, 49 (4) 344; DOI: https://doi.org/10.1124/dmd.120.000055err
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Correction to “Dimethandrolone, a Potential Male Contraceptive Pill, is Primarily Metabolized by the Highly Polymorphic UDP-Glucuronosyltransferase 2B17 Enzyme in Human Intestine and Liver”
  • Correction to “Identification of 5-Hydroxycotinine in the Plasma of Nicotine-Treated Mice: Implications for Cotinine Metabolism and Disposition in Vivo”
  • Correction to “Does Addition of Protein to Hepatocyte or Microsomal In Vitro Incubations Provide a Useful Improvement in In Vitro-In Vivo Extrapolation Predictability?”
Show more Erratum

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics